Denali Therapeutics Inc.

NAS: DNLI

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Denali Therapeutics Inc.

After Hours

--Quotes are delayed by 20 min

Nov 26, 2021, 4:13 p.m.

DNLI

/zigman2/quotes/200043077/composite

45.02

Change

0.00 0.00%

Volume

Volume 10,239

Quotes are delayed by 20 min

/zigman2/quotes/200043077/composite

Today's close

$ 47.64

$ 45.02

Change

-2.62 -5.50%

Day low

Day high

$44.12

$47.67

52 week low

52 week high

$43.81

$93.94

Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Denali Therapeutics Inc.

View Ratios

Fiscal year is January-December. All values USD millions.	2016	2017	2018	2019	2020	5-year trend
Sales/Revenue	-	-	129.16M	26.68M	335.66M
Sales Growth	-	-	-	-79.34%	1,158.19%
Cost of Goods Sold (COGS) incl. D&A	1.47M	3.08M	-	-	-
COGS excluding D&A	-	-	-	-	-
Depreciation & Amortization Expense	1.47M	3.08M	7.42M	7.99M	6.17M
Depreciation	1.47M	3.08M	7.42M	7.99M	6.17M
Amortization of Intangibles	-	-	-	-	-
COGS Growth	-	109.80%	-	-	-
Gross Income	(1.47M)	(3.08M)	-	-	-
Gross Income Growth	-	-109.80%	-	-	-
Gross Profit Margin	-	-	-	-	-	NA

	2016	2017	2018	2019	2020	5-year trend
SG&A Expense	85.96M	87.06M	160.22M	230.37M	266.77M
Research & Development	74.23M	71.38M	135.28M	191.88M	212.62M
Other SG&A	11.73M	15.68M	24.93M	38.49M	54.16M
SGA Growth	-	1.27%	84.03%	43.79%	15.80%
Other Operating Expense	-	-	-	-	-
Unusual Expense	-	-	8.1M	1.3M	(100,000)
EBIT after Unusual Expense	-	-	(46.57M)	(212.98M)	62.82M
Non Operating Income/Expense	-	-	-	-	-
Non-Operating Interest Income	781,000	1.96M	10.33M	15.02M	9.14M
Equity in Affiliates (Pretax)	-	-	-	-	-
Interest Expense	-	-	-	-	-
Interest Expense Growth	-	-	-	-	-
Gross Interest Expense	-	-	-	-	-
Interest Capitalized	-	-	-	-	-
Pretax Income	(86.65M)	(88.19M)	(36.24M)	(197.97M)	71.96M
Pretax Income Growth	-	-1.77%	58.90%	-446.26%	136.35%
Pretax Margin	-	-	-	-	21.44%	NA
Income Tax	-	-	-	(351,000)	823,000
Income Tax - Current Domestic	-	-	-	-	823,000
Income Tax - Current Foreign	-	-	-	-	-
Income Tax - Deferred Domestic	-	-	-	-	-
Income Tax - Deferred Foreign	-	-	-	-	-
Income Tax Credits	-	-	-	-	-
Equity in Affiliates	-	-	-	-	-
Other After Tax Income (Expense)	-	-	-	-	-
Consolidated Net Income	(86.65M)	(88.19M)	(36.24M)	(197.61M)	71.14M
Minority Interest Expense	-	-	-	-	-
Net Income	(86.65M)	(88.19M)	(36.24M)	(197.61M)	71.14M
Net Income Growth	-	-1.77%	58.90%	-445.29%	136.00%
Net Margin Growth	-	-	-	-	21.19%	NA
Extraordinaries & Discontinued Operations	-	-	-	-	-
Extra Items & Gain/Loss Sale Of Assets	-	-	-	-	-
Cumulative Effect - Accounting Chg	-	-	-	-	-
Discontinued Operations	-	-	-	-	-
Net Income After Extraordinaries	(86.65M)	(88.19M)	(36.24M)	(197.61M)	71.14M
Preferred Dividends	-	-	-	-	-
Net Income Available to Common	(86.65M)	(88.19M)	(36.24M)	(197.61M)	71.14M
EPS (Basic)	(0.96)	(5.89)	(0.39)	(2.07)	0.65
EPS (Basic) Growth	-	-512.20%	93.36%	-428.21%	131.58%
Basic Shares Outstanding	90.06M	14.96M	92.62M	95.61M	108.97M
EPS (Diluted)	(0.96)	(5.89)	(0.39)	(2.07)	0.63
EPS (Diluted) Growth	-	-512.20%	93.36%	-428.21%	130.54%
Diluted Shares Outstanding	90.06M	14.96M	92.62M	95.61M	112.7M
EBITDA	(85.96M)	(87.06M)	(31.06M)	(203.69M)	68.89M
EBITDA Growth	-	-1.27%	64.33%	-555.87%	133.82%
EBITDA Margin	-	-	-	-	20.52%	NA

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Denali Therapeutics Inc.

Annual Financials for Denali Therapeutics Inc.

Latest News

dow

nasdaq

s&p 500

Kiosk